Common mild side effects include red urine, soreness at the injection site, or a mild rash
New Zealand Research has primarily focused on its mechanisms of action, which suggest an enhancement in the processes of angiogenesis (the development of new blood vessels), tissue granulation, and collagen reformation
None of the products listed have been evaluated or approved by the FDA, MHRA, Health Canada, TGA, or any equivalent regulatory body for clinical, diagnostic, or therapeutic use
176 GLP-1RAs and diseases As a rising star in recent years, GLP-1RAs are not only effective in metabolic diseases but also play a role in non-metabolic disorders, affecting multiple systems including the musculoskeletal, nervous, cardiovascular, and digestive systems, and can even have implications in oncological diseases
doi: 10.3390/ijms17050629 [DOI] [PMC free article] [PubMed] [Google Scholar] 30.Wiraguna AAGP, Hari ED, Praharsini IGAA